Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Status:
RECRUITING
Trial end date:
2029-12-30
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.